59. Cassidy P, Radda G (2005) Molecular imaging perspectives. J R Soc Interface 2:133–144
60. Alberti C (2012) From molecular imaging in preclinical/clinical oncology to theranostic
applications in targeted tumor therapy. Eur Rev Med Pharmacol Sci 16:925–933
61. Dang X, Bardhan N, Qi J et al (2019) Deep-tissue optical imaging of near cellular-sized
features. Sci Rep 9:3873
62. Haque A, Faizi MSH, Rather JA et al (2017) Next generation NIR fluorophores for tumor
imaging and fluorescence-guided surgery: a review. Bioorg Med Chem 25:2017–2034
63. Hong G, Lee JC, Robinson JT et al (2012) Multifunctional in vivo vascular imaging using
near-infrared II fluorescence. Nat Med 18:1841–1846
64. Condeelis J, Weissleder R (2010) In vivo imaging in cancer. Cold Spring Harb Perspect Biol 2:
a003848
65. Thompson A, Hughes M, Anastasova S et al (2017) Position paper: the potential role of optical
biopsy in the study and diagnosis of environmental enteric dysfunction. Nat Rev Gastroenterol
Hepatol 14:727–738
66. Wang T, van dam J (2004) Optical biopsy: a new frontier in endoscopic detection and
diagnosis. Clin Gastroenterol Hepatol 2:744–753
67. Calzada V, Moreno M, Newton J et al (2017) Development of new PTK7-targeting aptamerfluorescent and -radiolabelled probes for evaluation as molecular imaging agents: lymphoma
and melanoma in vivo proof of concept. Bioorg Med Chem 25:1163–1171
68. Farrar C, Christopher M, Hudry E et al (2014) RNA aptamer probes as optical imaging agents
for the detection of amyloid plaques. PLoS One 9:e89901
69. Calzada V, Báez J, Sicco J et al (2017) Preliminary in vivo characterization of a theranostic
aptamer: Sgc8-cDOTA-67Ga. Aptamers 1:19–27
70. Wu X, Chen J, Wu M et al (2015) Aptamers: active targeting ligands for cancer diagnosis and
therapy. Theranostics 5:322–344
71. Wu X, Zhao Z, Bai H et al (2015) Aptamer selected against pancreatic ductal adenocarcinoma
for in vivo imaging and clinical tissue recognition. Theranostics 5:985–994
72. Li C, Kuo T, Su H et al (2015) Fluorescence-guided probes of aptamer-targeted gold
nanoparticles with computed tomography imaging accesses for in vivo tumor resection. Sci
Rep 5:15675
73. Sharma T, Bruno J, Dhiman A (2017) ABCs of DNA aptamer and related assay development.
Biotechnol Adv 35:275–301
74. Shi H, He X, Wang K et al (2011) Activatable aptamer probe for contrast-enhanced in vivo
cancer imaging based on cell membrane protein-triggered conformation alteration. Proc Natl
Acad Sci U S A 108:3900–3905
75. Wang A, Farokhzad O (2014) Current progress of aptamer-based molecular imaging. J Nucl
Med 55:353–356
76. Tang J, Huang N, Zhang X et al (2017) Aptamer-conjugated PEGylated quantum dots
targeting epidermal growth factor receptor variant III for fluorescence imaging of glioma. Int
J Nanomedicine 12:3899–3911
77. Samimi E, Karami P, Ahar M (2017) A review on aptamer conjugated quantum dot
nanosystems for cancer imaging and theranostic. J Nanomed Res 5:00117
78. Wu P, Yan X (2013) Doped quantum dots for chemo/biosensing and bioimaging. Chem Soc
Rev 42:5489–5521
79. Zhang C, Ji X, Zhang Y et al (2013) One-pot synthesized aptamer-functionalized CdTe:Zn2+
quantum dots for tumor-targeted fluorescence imaging in vitro and in vivo. Anal Chem
85:5843–5849
80. Kim D, Jeong Y, Jon S (2010) A drug-loaded aptamer-gold nanoparticle bioconjugate for
combined CT imaging and therapy of prostate cancer. ACS Nano 4:3689–3696
81. Kuo T, Lai W, Li C et al (2014) AS1411 aptamer-conjugated Gd2O3:Eu nanoparticles for
target-specific computed tomography/magnetic resonance/fluorescence molecular imaging.
Nano Res 7:658–669
Aptamers in Diagnostic and Molecular Imaging Applications
159
60. Alberti C (2012) From molecular imaging in preclinical/clinical oncology to theranostic
applications in targeted tumor therapy. Eur Rev Med Pharmacol Sci 16:925–933
61. Dang X, Bardhan N, Qi J et al (2019) Deep-tissue optical imaging of near cellular-sized
features. Sci Rep 9:3873
62. Haque A, Faizi MSH, Rather JA et al (2017) Next generation NIR fluorophores for tumor
imaging and fluorescence-guided surgery: a review. Bioorg Med Chem 25:2017–2034
63. Hong G, Lee JC, Robinson JT et al (2012) Multifunctional in vivo vascular imaging using
near-infrared II fluorescence. Nat Med 18:1841–1846
64. Condeelis J, Weissleder R (2010) In vivo imaging in cancer. Cold Spring Harb Perspect Biol 2:
a003848
65. Thompson A, Hughes M, Anastasova S et al (2017) Position paper: the potential role of optical
biopsy in the study and diagnosis of environmental enteric dysfunction. Nat Rev Gastroenterol
Hepatol 14:727–738
66. Wang T, van dam J (2004) Optical biopsy: a new frontier in endoscopic detection and
diagnosis. Clin Gastroenterol Hepatol 2:744–753
67. Calzada V, Moreno M, Newton J et al (2017) Development of new PTK7-targeting aptamerfluorescent and -radiolabelled probes for evaluation as molecular imaging agents: lymphoma
and melanoma in vivo proof of concept. Bioorg Med Chem 25:1163–1171
68. Farrar C, Christopher M, Hudry E et al (2014) RNA aptamer probes as optical imaging agents
for the detection of amyloid plaques. PLoS One 9:e89901
69. Calzada V, Báez J, Sicco J et al (2017) Preliminary in vivo characterization of a theranostic
aptamer: Sgc8-cDOTA-67Ga. Aptamers 1:19–27
70. Wu X, Chen J, Wu M et al (2015) Aptamers: active targeting ligands for cancer diagnosis and
therapy. Theranostics 5:322–344
71. Wu X, Zhao Z, Bai H et al (2015) Aptamer selected against pancreatic ductal adenocarcinoma
for in vivo imaging and clinical tissue recognition. Theranostics 5:985–994
72. Li C, Kuo T, Su H et al (2015) Fluorescence-guided probes of aptamer-targeted gold
nanoparticles with computed tomography imaging accesses for in vivo tumor resection. Sci
Rep 5:15675
73. Sharma T, Bruno J, Dhiman A (2017) ABCs of DNA aptamer and related assay development.
Biotechnol Adv 35:275–301
74. Shi H, He X, Wang K et al (2011) Activatable aptamer probe for contrast-enhanced in vivo
cancer imaging based on cell membrane protein-triggered conformation alteration. Proc Natl
Acad Sci U S A 108:3900–3905
75. Wang A, Farokhzad O (2014) Current progress of aptamer-based molecular imaging. J Nucl
Med 55:353–356
76. Tang J, Huang N, Zhang X et al (2017) Aptamer-conjugated PEGylated quantum dots
targeting epidermal growth factor receptor variant III for fluorescence imaging of glioma. Int
J Nanomedicine 12:3899–3911
77. Samimi E, Karami P, Ahar M (2017) A review on aptamer conjugated quantum dot
nanosystems for cancer imaging and theranostic. J Nanomed Res 5:00117
78. Wu P, Yan X (2013) Doped quantum dots for chemo/biosensing and bioimaging. Chem Soc
Rev 42:5489–5521
79. Zhang C, Ji X, Zhang Y et al (2013) One-pot synthesized aptamer-functionalized CdTe:Zn2+
quantum dots for tumor-targeted fluorescence imaging in vitro and in vivo. Anal Chem
85:5843–5849
80. Kim D, Jeong Y, Jon S (2010) A drug-loaded aptamer-gold nanoparticle bioconjugate for
combined CT imaging and therapy of prostate cancer. ACS Nano 4:3689–3696
81. Kuo T, Lai W, Li C et al (2014) AS1411 aptamer-conjugated Gd2O3:Eu nanoparticles for
target-specific computed tomography/magnetic resonance/fluorescence molecular imaging.
Nano Res 7:658–669
Aptamers in Diagnostic and Molecular Imaging Applications
159